2.Spatial and temporal distribution of newly diagnosed echinococcosis patients in Sichuan Province from 2007 to 2017
Wei HE ; Sha LIAO ; Qian WANG ; Yan HUANG ; Wen-Jie YU ; Guang-Jia ZHANG ; Qi WANG ; Liu YANG ; Fan CHEN ; Rui-Rui LI ; Bo ZHONG
Chinese Journal of Schistosomiasis Control 2019;31(4):393-399
Objective To explore the spatial and temporal distribution characteristics of cases with newly diagnosed echinococcosis in Sichuan Province from 2007 to 2017, so as to provide reference for the formulation of echinococcosis prevention and control strategies and for the identification of key areas. Methods The spatial distribution maps of detection of cases with newly diagnosed echinococcosis were plotted in Sichuan Province from 2007 to 2017, and the spatial distribution characteristics and epidemic trends were analyzed. Results From 2007 to 2017, the detection rate of cases with newly diagnosed echinococcosis appeared a decline in Sichuan Province year by year, and the areas with a high detection rate of cases with newly diagnosed echinococcosis were mainly located in western, northwestern and northern parts of Sichuan Province, while the areas with a low detection rate were predominantly found in the southern and eastern parts of the province. The global Moran’s I values were 0.19, 0.22, 0.17, 0.44, 0.48, 0.31 and 0.16 for the detection rate of cases with newly diagnosed echinococcosis in Sichuan Province from 2010 to 2016 (all Z scores > 1.96, all P values < 0.05), suggesting spatial aggregation distribution during this period. Local spatial autocorrelation analysis revealed that the“high-high”areas and“low-low”areas for the detection rate of cases with newly diagnosed echinococcosis all showed an aggregation tendency. Conclusions The detection rate of cases with newly diagnosed echinococcosis decreases in Sichuan Province from 2007 to 2017 year by year, and shows a spatial aggregation. The echinococcosis control activities should be intensified in Shiqu, Seda, Dege, Ganzi and Baiyu counties.
3.Risk factors of human cystic echinococcosis in Shiqu County Sichuan Province: a case-control study
Wei HE ; Qian WANG ; Yan HUANG ; Wen-Jie YU ; Guang-Jia ZHANG ; Sha LIAO ; Qi WANG ; Liu YANG ; Fan CHEN ; Rui-Rui LI ; Bo ZHONG
Chinese Journal of Schistosomiasis Control 2019;31(5):486-490
Objective To identify the main risk factors of human cystic echinococcosis in Shiqu County, Sichuan Province, so as to provide the reference for the formulation of echinococcosis control strategies in Shiqu County. Methods During the period from November 2015 through June 2017, the patients with cystic echinococcosis (case group) and healthy controls (control group) were randomly sampled from Shiqu County as the study subjects. A questionnaire survey was conducted to capture the study subjects’age, gender, ethnicity, occupation, religion, lifestyle, education level, number of household dogs, bovine and sheep, and density of dog feces in the courtyard. The major risk factors of human cystic echinococcosis were identified using a logistic regression model. Results Univariate logistic regression analysis showed 7 risk factors with statistical significance between the case and control groups, and age, lifestyle, number of household bovine, number of household sheep, number of house-hold dogs, and the density of dog feces in the courtyard were included in the multivariate logistic regression model (OR = 1.026, 4.792, 1.067, 1.022, 1.709 and 1.095, respectively). Conclusion High age, pastoral nomadic lifestyle, high number of house-hold bovine, high number of household sheep, high number of household dogs and high density of dog feces in the courtyard are strongly associated with the riks of human cystic echinococcosis in Shiqu County.
4. Clinical deep remission and related factors in a large cohort of patients with rheumatoid arthritis
Jia-Jia LIU ; Ru LI ; Yu-Zhou GAN ; Rui-Jun ZHANG ; Jing LI ; Yue-Ming CAI ; Jin-Xia ZHAO ; Hua LIAO ; Jing XU ; Lian-Jie SHI ; Ji LI ; Sheng-Guang LI ; Xiao-Lin SUN ; Jing HE ; Xu LIU ; Hua YE ; Zhan-Guo LI
Chinese Medical Journal 2019;132(9):1009-1014
Background::
Clinical remission is the treatment target in rheumatoid arthritis (RA). This study aimed to investigate clinical remission and related factors in a large cohort of patients with RA.
Methods::
This study composed of 342 patients with RA. Data were collected by face-to-face interview of 1049 patients with RA who visited the Department of Rheumatology of three teaching hospitals from September 2015 to May 2016. The patients with RA were clinically assessed by rheumatologists and a four-page questionnaire was completed on site. Subsequently, patients fulfilled remission criteria were further analyzed. The practicability of different definitions of remission of RA was rated by a panel of rheumatologists. Sustained intensive disease modifying anti-rheumatic drug (DMARD) treatment was defined as a combination treatment with two or more DMARDs for at least 6 months.
Results::
In this cohort of 342 patients with RA, the proportions of patients achieving remission were 38.0%, 29.5%, 24.9%, 21.1%, 19.0%, 18.1%, and 17.0%, based on criteria of disease activity score in 28 joints (DAS28) using CRP (DAS28-CRP), DAS28 using ESR (DAS28-ESR), routine assessment of patient index data 3 (RAPID-3), Boolean, simplified disease activity index (SDAI), clinical disease activity index, and the newly described clinical deep remission (CliDR), respectively. Boolean and CliDR are the best in practicability scored by rheumatologists (7.5 and 8.0, respectively). Compared with the non-sustained intensive group, sustained intensive treatment with DMARDs yielded higher remission rates of 25.6%, 23.8%, and 21.3% in patients with RA based on Boolean (
5.Clinical deep remission and related factors in a large cohort of patients with rheumatoid arthritis.
Jia-Jia LIU ; Ru LI ; Yu-Zhou GAN ; Rui-Jun ZHANG ; Jing LI ; Yue-Ming CAI ; Jin-Xia ZHAO ; Hua LIAO ; Jing XU ; Lian-Jie SHI ; Ji LI ; Sheng-Guang LI ; Xiao-Lin SUN ; Jing HE ; Xu LIU ; Hua YE ; Zhan-Guo LI
Chinese Medical Journal 2019;132(9):1009-1014
BACKGROUND:
Clinical remission is the treatment target in rheumatoid arthritis (RA). This study aimed to investigate clinical remission and related factors in a large cohort of patients with RA.
METHODS:
This study composed of 342 patients with RA. Data were collected by face-to-face interview of 1049 patients with RA who visited the Department of Rheumatology of three teaching hospitals from September 2015 to May 2016. The patients with RA were clinically assessed by rheumatologists and a four-page questionnaire was completed on site. Subsequently, patients fulfilled remission criteria were further analyzed. The practicability of different definitions of remission of RA was rated by a panel of rheumatologists. Sustained intensive disease modifying anti-rheumatic drug (DMARD) treatment was defined as a combination treatment with two or more DMARDs for at least 6 months.
RESULTS:
In this cohort of 342 patients with RA, the proportions of patients achieving remission were 38.0%, 29.5%, 24.9%, 21.1%, 19.0%, 18.1%, and 17.0%, based on criteria of disease activity score in 28 joints (DAS28) using CRP (DAS28-CRP), DAS28 using ESR (DAS28-ESR), routine assessment of patient index data 3 (RAPID-3), Boolean, simplified disease activity index (SDAI), clinical disease activity index, and the newly described clinical deep remission (CliDR), respectively. Boolean and CliDR are the best in practicability scored by rheumatologists (7.5 and 8.0, respectively). Compared with the non-sustained intensive group, sustained intensive treatment with DMARDs yielded higher remission rates of 25.6%, 23.8%, and 21.3% in patients with RA based on Boolean (χ = 3.937, P = 0.047), SDAI (χ = 4.666, P = 0.031), and CliDR criteria (χ = 4.297, P = 0.038). The most commonly prescribed conventional synthesized DMARDs (csDMARDs) in patients with RA was leflunomide, followed by methotrexate, and hydroxychloroquine. Compared with the non-remission group, patients achieving remission had a longer median duration of DMARDs (45.0 [22.8-72.3] months, Z = -2.295, P = 0.022).
CONCLUSIONS
The findings in this study indicated that clinical deep remission is achievable in patients with RA. Sustained intensive DMARD treatment is needed to achieve a better outcome in RA.
Adult
;
Aged
;
Antirheumatic Agents
;
therapeutic use
;
Arthritis, Rheumatoid
;
drug therapy
;
pathology
;
Cross-Sectional Studies
;
Female
;
Humans
;
Hydroxychloroquine
;
therapeutic use
;
Leflunomide
;
therapeutic use
;
Male
;
Methotrexate
;
therapeutic use
;
Middle Aged
;
Retrospective Studies
;
Surveys and Questionnaires
6.Design of an interactive management system between doctors and echinococcosis patients in Sichuan Province
Guang-jia ZHANG ; Sha LIAO ; Yi-fei WANG ; Yan HUANG ; Wen-jie YU ; Wei HE ; Qi WANG ; Rui-rui LI ; Fan CHEN ; Liu YANG ; Bo ZHONG ; Qian WANG
Chinese Journal of Schistosomiasis Control 2018;30(5):581-582
Objective To design and construct a patient-doctor interaction system for echinococcosis treatment. Methods The in-depth interview and brainstorming method were used to determine the main functional modules of the system based on the server/client model. Results An echinococcosis patient-doctor interaction system was successfully constructed in Sichuan Province and got through preliminary debugging. The system contained four functions, namely quick consultation, treatment supervision, health education, and other auxiliary functions. Conclusion The patient-doctor interaction system of echinococcosis treatment is hopeful to enhance the management effectiveness on echinococcosis patients, and to provide more convenient and quick medical consultation and health information for patients.
7.Relationship between Apolipoprotein Superfamily and Parkinson's Disease.
Lin LI ; Ming-Su LIU ; Guang-Qin LI ; Jie TANG ; Yan LIAO ; Yang ZHENG ; Tong-Li GUO ; Xin KANG ; Mao-Ting YUAN
Chinese Medical Journal 2017;130(21):2616-2623
OBJECTIVEParkinson's disease (PD) is featured with motor disorder and nonmotor manifestations including psychological symptoms, autonomic nervous system dysfunction, and paresthesia, which results in great inconvenience to the patients' life. The apolipoprotein (Apo) superfamily, as a group of potentially modifiable biomarkers in clinical practice, is of increasing significance in the diagnosis, evaluation, and prognosis of PD. The present review summarized the current understanding and emerging findings of the relationship between Apo superfamily and PD.
DATA SOURCESAll literatures were identified by systematically searching PubMed, Embase, and Cochrane electronic databases with terms "Parkinson disease," "apolipoprotein," and their synonyms until May 2017.
STUDY SELECTIONWe have thoroughly examined titles and abstracts of all the literatures that met our search strategy and the full text if the research is identified or not so definite. Reference lists of retrieved articles were also scrutinized for additional relevant studies.
RESULTSThe levels of plasma ApoA1 are inversely correlated with the risk of PD and the lower levels of ApoA1 trend toward association with poorer motor performance. Higher ApoD expression in neurons represents more puissant protection against PD, which is critical in delaying the neurodegeneration process of PD. It is suggested that APOE alleles are related to development and progression of cognitive decline and age of PD onset, but conclusions are not completely identical, which may be attributed to different ApoE isoforms. APOJ gene expressions are upregulated in PD patients and it is possible that high ApoJ level is an indicator of PD dementia and correlates with specific phenotypic variations in PD.
CONCLUSIONSThe Apo superfamily has been proved to be closely involved in the initiation, progression, and prognosis of PD. Apos and their genes are of great value in predicting the susceptibility of PD and hopeful to become the target of medical intervention to prevent the onset of PD or slow down the progress. Therefore, further large-scale studies are warranted to elucidate the precise mechanisms of Apos in PD.
8.Induction of robust senescence-associated secretory phenotype in mouse NIH-3T3 cells by mitomycin C.
Wei-Xing HUANG ; Xiao-Xuan GUO ; Zhong-Zhi PENG ; Chun-Liang WENG ; Chun-Yan HUANG ; Ben-Yan SHI ; Jie YANG ; Xiao-Xin LIAO ; Xiao-Yi LI ; Hui-Ling ZHENG ; Xin-Guang LIU ; Xue-Rong SUN
Acta Physiologica Sinica 2017;69(1):33-40
Senescence-associated secretory phenotype (SASP) is often a concomitant result of cell senescence, embodied by the enhanced function of secretion. The SASP factors secreted by senescent cells include cytokines, proteases and chemokines, etc, which can exert great influence on local as well as systemic environment and participate in the process of cell senescence, immunoregulation, angiogenesis, cell proliferation and tumor invasion, etc. Relative to the abundance of SASP models in human cells, the in vitro SASP model derived from mouse cells is scarce at present. Therefore, the study aimed to establish a mouse SASP model to facilitate the research in the field. With this objective, we treated the INK4a-deficient mouse NIH-3T3 cells and the wildtype mouse embryonic fibroblasts (MEF) respectively with mitomycin C (MMC), an anticarcinoma drug which could induce DNA damage. The occurring of cell senescence was evaluated by cell morphology, β-gal staining, integration ratio of EdU and Western blot. Quantitative RT-PCR and ELISA were used to detect the expression and secretion of SASP factors, respectively. The results showed that, 8 days after the treatment of NIH-3T3 cells with MMC (1 μg/mL) for 12 h or 24 h, the cells became enlarged and the ratios of β-gal-positive (blue-stained) cells significantly increased, up to 77.4% and 90.4%, respectively. Meanwhile, the expression of P21 protein increased and the integration ratios of EdU significantly decreased (P < 0.01). Quantitative RT-PCR detection showed that the mRNA levels of several SASP genes, including IL-6, TNF-α, IL-1α and IL-1β increased evidently. ELISA detection further observed an enhanced secretion of IL-6 (P < 0.01). On the contrary, although wildtype MEF could also be induced into senescence by MMC treatment for 12 h or 24 h, embodied by the enlarged cell volume, increased ratios of β-gal-positive cells (up to 71.7% and 80.2%, respectively) and enhanced expression of P21 protein, the secretion of IL-6 displayed no significant change. Our study indicated that, although MMC could induce senescence in both mouse NIH-3T3 cells and wildtype MEF, only senescent NIH-3T3 cells displayed the canonical SASP phenomena. Current study suggested that senescent NIH-3T3 cells might be an appropriate in vitro SASP model of mouse cells.
Animals
;
Cell Proliferation
;
Cellular Senescence
;
drug effects
;
Cyclin-Dependent Kinase Inhibitor p21
;
genetics
;
metabolism
;
Cytokines
;
genetics
;
metabolism
;
DNA Damage
;
Fibroblasts
;
drug effects
;
Interleukin-6
;
secretion
;
Mice
;
Mitomycin
;
pharmacology
;
NIH 3T3 Cells
;
Phenotype
9.Clinical Application of Disease-syndrome Combination and Formula-syndrome Relation
Jie WANG ; Xingjiang XIONG ; Jiangquan LIAO ; Wenrui JIANG ; Yan DONG ; Guang CHEN
World Science and Technology-Modernization of Traditional Chinese Medicine 2017;19(3):387-391
The traditional conotation of combination of disease and syndrome means the combination of disease differentiation in traditional Chinese medicine (TCM) diseases and TCM syndrome differentiation,which was derived from the Yellow Emperor's Inner Classic.And the Treatise on Cold Damage and Miscellaneous Diseases describes the clinical application of this theory.Under the background of integrative medicine,the modern conotation of combination of disease and syndrome means TCM syndrome differentiation and treatment based on modern medicine disease differentiation,which is commonly used in the current clinical practice.The disease and syndrome combination diagnosis mode based on syndrome,etiology,pathology and pharmacology can understand the disease from a multiple and comprehensive level,in order to realize the combination and complementation of advantages from both medicines.In addition,formula-syndrome relation means the relationship between the formula and its relevant indications.In general,indications often involve syndromes,symptoms,diseases and body constitutions.And the application of formula in the Treatise on Cold Damage and Miscellaneous Diseases is the representative of this theory.Hence,the application of associated classical formula gives example to the clinical formula-syndrome relation application in modem times.
10.Relationship between Apolipoprotein Superfamily and Parkinson's Disease
Li LIN ; Liu MING?SU ; Li GUANG?QIN ; Tang JIE ; Liao YAN ; Zheng YANG ; Guo TONG?LI ; Kang XIN ; Yuan MAO?TING
Chinese Medical Journal 2017;(21):2616-2623
Objective: Parkinson's disease (PD) is featured with motor disorder and nonmotor manifestations including psychological symptoms, autonomic nervous system dysfunction, and paresthesia, which results in great inconvenience to the patients'life. The apolipoprotein (Apo) superfamily, as a group of potentially modifiable biomarkers in clinical practice, is of increasing significance in the diagnosis, evaluation, and prognosis of PD. The present review summarized the current understanding and emerging findings of the relationship between Apo superfamily and PD. Data Sources:All literatures were identified by systematically searching PubMed, Embase, and Cochrane electronic databases with terms"Parkinson disease," "apolipoprotein," and their synonyms until May 2017. Study Selection: We have thoroughly examined titles and abstracts of all the literatures that met our search strategy and the full text if the research is identified or not so definite. Reference lists of retrieved articles were also scrutinized for additional relevant studies. Results: The levels of plasma ApoA1 are inversely correlated with the risk of PD and the lower levels of ApoA1 trend toward association with poorer motor performance. Higher ApoD expression in neurons represents more puissant protection against PD, which is critical in delaying the neurodegeneration process of PD. It is suggested that APOE alleles are related to development and progression of cognitive decline and age of PD onset, but conclusions are not completely identical, which may be attributed to different ApoE isoforms. APOJ gene expressions are upregulated in PD patients and it is possible that high ApoJ level is an indicator of PD dementia and correlates with specific phenotypic variations in PD. Conclusions: The Apo superfamily has been proved to be closely involved in the initiation, progression, and prognosis of PD. Apos and their genes are of great value in predicting the susceptibility of PD and hopeful to become the target of medical intervention to prevent the onset of PD or slow down the progress. Therefore, further large?scale studies are warranted to elucidate the precise mechanisms of Apos in PD.

Result Analysis
Print
Save
E-mail